An announcement from Indaptus Therapeutics (INDP) is now available.
During the Company’s Annual Meeting on June 6, 2024, with over 50% of outstanding Common Stock represented, three Class III directors were elected, and two key proposals were approved. The directors will serve until the 2027 annual meeting, and their election received a significant majority of the votes. Additionally, the Company ratified the appointment of Haskell & White LLP as its independent accounting firm for the upcoming fiscal year and approved the amendment and restatement of the Plan, which includes an increase in available shares for issuance and an extension of the evergreen provision.
Find detailed analytics on INDP stock on TipRanks’ Stock Analysis page.
